{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:04:26Z","timestamp":1787162666565,"version":"build-2736575974"},"reference-count":126,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82022040, 81874233"],"award-info":[{"award-number":["82022040, 81874233"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cancer immunotherapy can boost the immune response of patients to eliminate tumor cells and suppress tumor metastasis and recurrence. However, immunotherapy resistance and the occurrence of severe immune-related adverse effects are clinical challenges that remain to be addressed. The tumor microenvironment plays a crucial role in the therapeutic efficacy of cancer immunotherapy. Injectable hydrogels have emerged as powerful drug delivery platforms offering good biocompatibility and biodegradability, minimal invasion, convenient synthesis, versatility, high drug-loading capacity, controlled drug release, and low toxicity. In this review, we summarize the application of injectable hydrogels as a unique platform for targeting the immunosuppressive tumor microenvironment.<\/jats:p>","DOI":"10.3389\/fimmu.2021.832942","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T02:28:14Z","timestamp":1642386494000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment"],"prefix":"10.3389","volume":"12","author":[{"given":"Yushuai","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beilei","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pui-Chi","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the Year 2013. Cancer Immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673","article-title":"Cancer Immunotherapy Comes of Age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1039\/c8cs00896e","article-title":"Recent Advances in Nanomaterial-Based Synergistic Combination Cancer Immunotherapy","volume":"48","author":"Sang","year":"2019","journal-title":"Chem Soc Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-Related Adverse Events With Immune Checkpoint Blockade: A Comprehensive Review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addr.2017.05.011","article-title":"Delivering Safer Immunotherapies for Cancer","volume":"114","author":"Milling","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"ARTN 1902785","DOI":"10.1002\/adfm.201902785","article-title":"Smart Injectable Hydrogels for Cancer Immunotherapy","volume":"30","author":"Chao","year":"2020","journal-title":"Adv Funct Mater"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.8b05893","article-title":"Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy","volume":"12","author":"Musetti","year":"2018","journal-title":"ACS Nano"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201803322","article-title":"Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy","volume":"31","author":"Phuengkham","year":"2019","journal-title":"Adv Mater"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the Tumor Microenvironment: Removing Obstruction to Anticancer Immune Responses and Immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.209","article-title":"Combination Cancer Immunotherapies Tailored to the Tumour Microenvironment","volume":"13","author":"Smyth","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1039\/c1cs15203c","article-title":"Injectable and Biodegradable Hydrogels: Gelation, Biodegradation and Biomedical Applications","volume":"41","author":"Li","year":"2012","journal-title":"Chem Soc Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.07.006","article-title":"Injectable Hydrogel-Based Drug Delivery Systems for Local Cancer Therapy","volume":"21","author":"Norouzi","year":"2016","journal-title":"Drug Discov Today"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.6b00536","article-title":"Designing Hydrogels for On-Demand Therapy","volume":"50","author":"Oliva","year":"2017","journal-title":"Acc Chem Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.1214804","article-title":"Designing Cell-Compatible Hydrogels for Biomedical Applications","volume":"336","author":"Seliktar","year":"2012","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.201800240","article-title":"Injectable Hydrogels as Unique Platforms for Local Chemotherapeutics-Based Combination Antitumor Therapy","volume":"18","author":"Yu","year":"2018","journal-title":"Macromol Biosci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2019.00675","article-title":"Injectable Hydrogels for Localized Cancer Therapy","volume":"7","author":"Fan","year":"2019","journal-title":"Front Chem"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1039\/c4cc05614k","article-title":"Synergistic Dual-Targeting Hydrogel Improves Targeting and Anticancer Effect of Taxol In Vitro and In Vivo","volume":"50","author":"Shu","year":"2014","journal-title":"Chem Commun (Camb)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2019.01.122","article-title":"Dual Thermo-and pH-Sensitive Injectable Hydrogels of Chitosan\/(Poly(N-Isopropylacrylamide-Co-Itaconic Acid)) for Doxorubicin Delivery in Breast Cancer","volume":"128","author":"Fathi","year":"2019","journal-title":"Int J Biol Macromol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2703","article-title":"Innate and Adaptive Immune Cells in the Tumor Microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80005","article-title":"Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Expect the Unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The Immune Contexture in Human Tumours: Impact on Clinical Outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer Immunoediting: Integrating Immunity\u2019s Roles in Cancer Suppression and Promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nri3740","article-title":"T Cell Differentiation in Chronic Infection and Cancer: Functional Adaptation or Exhaustion","volume":"14","author":"Speiser","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer Immunotherapy Using Checkpoint Blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/srep15179","article-title":"Prognostic Value of Tumor-Infiltrating FoxP3+ Regulatory T Cells in Cancers: A Systematic Review and Meta-Analysis","volume":"5","author":"Shang","year":"2015","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2618","article-title":"Microenvironmental Regulation of Metastasis","volume":"9","author":"Joyce","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The Future of Immune Checkpoint Therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aao1736","article-title":"Elimination of Established Tumors With Nanodisc-Based Combination Chemoimmunotherapy","volume":"4","author":"Kuai","year":"2018","journal-title":"Sci Adv"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers, and Combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and Activity of Anti-PD-L1 Antibody in Patients With Advanced Cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and Tumor Responses With Lambrolizumab (Anti-PD-1) in Melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (Anti-PD-L1) Treatment Leads to Clinical Activity in Metastatic Bladder Cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in Previously Untreated Melanoma Without BRAF Mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab Versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in Cancer Immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.02.004","article-title":"Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade","volume":"29","author":"Tang","year":"2016","journal-title":"Cancer Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-Driven Biomarkers to Guide Immune Checkpoint Blockade in Cancer Therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety Profiles of Anti-CTLA-4 and Anti-PD-1 Antibodies Alone and in Combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis With Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201402105","article-title":"Hydrogels and Scaffolds for Immunomodulation","volume":"26","author":"Singh","year":"2014","journal-title":"Adv Mater"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz8985","article-title":"Supramolecular Prodrug Hydrogelator as an Immune Booster for Checkpoint Blocker-Based Immunotherapy","volume":"6","author":"Wang","year":"2020","journal-title":"Sci Adv"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting Immunogenic Cell Death in Cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"370ra180","DOI":"10.1126\/scitranslmed.aag2942","article-title":"Anti-PD-1 Antitumor Immunity Is Enhanced by Local and Abrogated by Systemic Chemotherapy in GBM","volume":"8","author":"Mathios","year":"2016","journal-title":"Sci Transl Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajps.2020.05.004","article-title":"Role of Nanoparticle-Mediated Immunogenic Cell Death in Cancer Immunotherapy","volume":"16","author":"Sun","year":"2021","journal-title":"Asian J Pharm Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"eaan3682","DOI":"10.1126\/scitranslmed.aan3682","article-title":"In Situ Formed Reactive Oxygen Species-Responsive Scaffold With Gemcitabine and Checkpoint Inhibitor for Combination Therapy","volume":"10","author":"Wang","year":"2018","journal-title":"Sci Transl Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201806957","article-title":"A Dual-Bioresponsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade","volume":"31","author":"Ruan","year":"2019","journal-title":"Adv Mater"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2104630","DOI":"10.1002\/adfm.202104630","article-title":"A Checkpoint-Regulatable Immune Niche Created by Injectable Hydrogel for Tumor Therapy","volume":"31","author":"Li","year":"2021","journal-title":"Adv Funct Mater"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/35105024","article-title":"T-Cell Regulation by CD28 and CTLA-4","volume":"1","author":"Alegre","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti-Cytotoxic T-Lymphocyte Antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2016-0385","article-title":"Ipilimumab: From Preclinical Development to Future Clinical Perspectives in Melanoma","volume":"13","author":"Letendre","year":"2017","journal-title":"Future Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0130-1","article-title":"Future Prospects of Immune Checkpoint Blockade in Cancer: From Response Prediction to Overcoming Resistance","volume":"50","author":"Park","year":"2018","journal-title":"Exp Mol Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2020.03.050","article-title":"Thermosensitive Hydrogels as Sustained Drug Delivery System for CTLA-4 Checkpoint Blocking Antibodies","volume":"323","author":"Chung","year":"2020","journal-title":"J Control Release"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02579-8","article-title":"Peri-Tumor Administration of Controlled Release Anti-CTLA-4 Synergizes With Systemic Anti-PD-1 to Induce Systemic Antitumor Immunity While Sparing Autoimmune Toxicity","volume":"69","author":"Harui","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.7150\/thno.30577","article-title":"Injectable Polypeptide Hydrogel-Based Co-Delivery of Vaccine and Immune Checkpoint Inhibitors Improves Tumor Immunotherapy","volume":"9","author":"Song","year":"2019","journal-title":"Theranostics"},{"key":"B61","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting Macrophages: Therapeutic Approaches in Cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.02.003","article-title":"Targeting Tumor-Associated Macrophages in Cancer","volume":"40","author":"Pathria","year":"2019","journal-title":"Trends Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/832454","article-title":"Regulation of Antitumor Immune Responses by the IL-12 Family Cytokines, IL-12, IL-23, and IL-27","volume":"2010","author":"Xu","year":"2010","journal-title":"Clin Dev Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201902007","article-title":"Progress on Modulating Tumor-Associated Macrophages With Biomaterials","volume":"32","author":"Sylvestre","year":"2020","journal-title":"Adv Mater"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1593\/neo.09988","article-title":"The Chemokine CCL2 Increases Prostate Tumor Growth and Bone Metastasis Through Macrophage and Osteoclast Recruitment","volume":"11","author":"Mizutani","year":"2009","journal-title":"Neoplasia"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nature10138","article-title":"CCL2 Recruits Inflammatory Monocytes to Facilitate Breast-Tumour Metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/565187","article-title":"Tumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy","volume":"2011","author":"Baay","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting Tumor-Associated Macrophages With Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18627","article-title":"Melittin Suppresses Tumor Progression by Regulating Tumor-Associated Macrophages in a Lewis Lung Carcinoma Mouse Model","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910510109","article-title":"Anti-Tumor and Immunomodulatory Activity of Intraperitoneal IFN-Gamma in Ovarian Carcinoma Patients With Minimal Residual Tumor After Chemotherapy","volume":"51","author":"Colombo","year":"1992","journal-title":"Int J Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198443","article-title":"CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"B72","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41467-017-01050-0","article-title":"Hollow MnO2 as a Tumor-Microenvironment-Responsive Biodegradable Nano-Platform for Combination Therapy Favoring Antitumor Immune Responses","volume":"8","author":"Yang","year":"2017","journal-title":"Nat Commun"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2017.09.004","article-title":"Targeting Tumor Associated Macrophages: The New Challenge for Nanomedicine","volume":"34","author":"Andon","year":"2017","journal-title":"Semin Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/nature13862","article-title":"Cessation of CCL2 Inhibition Accelerates Breast Cancer Metastasis by Promoting Angiogenesis","volume":"515","author":"Bonapace","year":"2014","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379214","article-title":"Therapeutic Applications of Macrophage Colony-Stimulating Factor-1 (CSF-1) and Antagonists of CSF-1 Receptor (CSF-1R) Signaling","volume":"119","author":"Hume","year":"2012","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.7b08148","article-title":"Tumor Ablation and Therapeutic Immunity Induction by an Injectable Peptide Hydrogel","volume":"12","author":"Jin","year":"2018","journal-title":"ACS Nano"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.7150\/thno.35434","article-title":"Development of Adamantane-Conjugated TLR7\/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy","volume":"9","author":"Rodell","year":"2019","journal-title":"Theranostics"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.7150\/thno.42385","article-title":"Targeting CAMKII to Reprogram Tumor-Associated Macrophages and Inhibit Tumor Cells for Cancer Immunotherapy With an Injectable Hybrid Peptide Hydrogel","volume":"10","author":"Dai","year":"2020","journal-title":"Theranostics"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1614035114","article-title":"Gpr132 Sensing of Lactate Mediates Tumor-Macrophage Interplay to Promote Breast Cancer Metastasis","volume":"114","author":"Chen","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1367","article-title":"Diverse Functions of Macrophages in Different Tumor Microenvironments","volume":"78","author":"Yang","year":"2018","journal-title":"Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.9b00618","article-title":"Repolarization of M2 to M1 Macrophages Triggered by Lactate Oxidase Released From Methylcellulose Hydrogel","volume":"30","author":"Liao","year":"2019","journal-title":"Bioconjug Chem"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97642","article-title":"Antigen Delivery Targeted to Tumor-Associated Macrophages Overcomes Tumor Immune Resistance","volume":"129","author":"Muraoka","year":"2019","journal-title":"J Clin Invest"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.029","article-title":"Alternatively Activated (M2) Macrophages Promote Tumour Growth and Invasiveness in Hepatocellular Carcinoma","volume":"62","author":"Yeung","year":"2015","journal-title":"J Hepatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.7150\/thno.20251","article-title":"The Anti-Tumor Effects of M1 Macrophage-Loaded Poly (Ethylene Glycol) and Gelatin-Based Hydrogels on Hepatocellular Carcinoma","volume":"7","author":"Guerra","year":"2017","journal-title":"Theranostics"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-020518-114700","article-title":"Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges","volume":"81","author":"Martin","year":"2019","journal-title":"Annu Rev Physiol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-017-9562-9","article-title":"Tumor Angiogenesis and Vascular Normalization: Alternative Therapeutic Targets","volume":"20","author":"Viallard","year":"2017","journal-title":"Angiogenesis"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the Vasculature for Treatment of Cancer and Other Diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol Rev"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/nm0603-669","article-title":"The Biology of VEGF and Its Receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular Normalizing Doses of Antiangiogenic Treatment Reprogram the Immunosuppressive Tumor Microenvironment and Enhance Immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0153","article-title":"Antiangiogenic Agents can Increase Lymphocyte Infiltration Into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer","volume":"70","author":"Shrimali","year":"2010","journal-title":"Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2017.06.028","article-title":"Alginate Hydrogel Improves Anti-Angiogenic Bevacizumab Activity in Cancer Therapy","volume":"119","author":"Ferreira","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"key":"B93","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jconrel.2019.07.028","article-title":"Inhibition of Breast Cancer Proliferation and Metastasis by Strengthening Host Immunity With a Prolonged Oxygen-Generating Phototherapy Hydrogel","volume":"309","author":"Zhou","year":"2019","journal-title":"J Control Release"},{"key":"B94","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bioeng.2006.01.002","article-title":"RNA Interference in Cancer","volume":"23","author":"Gartel","year":"2006","journal-title":"Biomol Eng"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S23696","article-title":"Nanoparticle-Based Delivery of Small Interfering RNA: Challenges for Cancer Therapy","volume":"7","author":"Miele","year":"2012","journal-title":"Int J Nanomed"},{"key":"B96","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0092-8674(00)80620-0","article-title":"RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals","volume":"101","author":"Zamore","year":"2000","journal-title":"Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12547","article-title":"Cycloamylose-Nanogel Drug Delivery System-Mediated Intratumor Silencing of the Vascular Endothelial Growth Factor Regulates Neovascularization in Tumor Microenvironment","volume":"105","author":"Fujii","year":"2014","journal-title":"Cancer Sci"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.21","article-title":"Antiangiogenic Therapy: Impact on Invasion, Disease Progression, and Metastasis","volume":"8","author":"Ebos","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-4354","article-title":"Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.9b00551","article-title":"A Localized Chimeric Hydrogel Therapy Combats Tumor Progression Through Alteration of Sphingolipid Metabolism","volume":"5","author":"Pal","year":"2019","journal-title":"ACS Cent Sci"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1039\/c8bm01442f","article-title":"Enhanced Local Cancer Therapy Using a CA4P and CDDP Co-Loaded Polypeptide Gel Depot","volume":"7","author":"Yu","year":"2019","journal-title":"Biomater Sci"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.7b08225","article-title":"Oxygen-Self-Produced Nanoplatform for Relieving Hypoxia and Breaking Resistance to Sonodynamic Treatment of Pancreatic Cancer","volume":"11","author":"Chen","year":"2017","journal-title":"ACS Nano"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.7b02533","article-title":"Cancer Cell Membrane Camouflaged Cascade Bioreactor for Cancer Targeted Starvation and Photodynamic Therapy","volume":"11","author":"Li","year":"2017","journal-title":"ACS Nano"},{"key":"B104","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1038\/s41467-019-13115-3","article-title":"Extravascular Gelation Shrinkage-Derived Internal Stress Enables Tumor Starvation Therapy With Suppressed Metastasis and Recurrence","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat Commun"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1172\/JCI64859","article-title":"Depleting Tumor-Specific Tregs at a Single Site Eradicates Disseminated Tumors","volume":"123","author":"Marabelle","year":"2013","journal-title":"J Clin Invest"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201801868","article-title":"Tumors and Their Microenvironment Dual-Targeting Chemotherapy With Local Immune Adjuvant Therapy for Effective Antitumor Immunity Against Breast Cancer","volume":"6","author":"Deng","year":"2019","journal-title":"Adv Sci (Weinh)"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119659","article-title":"Dual Fluorescence Imaging-Guided Programmed Delivery of Doxorubicin and CpG Nanoparticles to Modulate Tumor Microenvironment for Effective Chemo-Immunotherapy","volume":"230","author":"Dong","year":"2020","journal-title":"Biomaterials"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ Regulatory T Cells Suppress Tumor Immunity But Are Sensitive to Cyclophosphamide Which Allows Immunotherapy of Established Tumors to be Curative","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur J Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic Cyclophosphamide Regimen Selectively Depletes CD4+CD25+ Regulatory T Cells and Restores T and NK Effector Functions in End Stage Cancer Patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4(+)25+ T Regulatory Cell Function Implicated in Enhanced Immune Response by Low-Dose Cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25756","article-title":"Gemcitabine Depletes Regulatory T-Cells in Human and Mice and Enhances Triggering of Vaccine-Specific Cytotoxic T-Cells","volume":"129","author":"Rettig","year":"2011","journal-title":"Int J Cancer"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-008-9228-5","article-title":"Chitosan Hydrogel Containing GMCSF and a Cancer Drug Exerts Synergistic Anti-Tumor Effects via the Induction of CD8+ T Cell-Mediated Anti-Tumor Immunity","volume":"26","author":"Seo","year":"2009","journal-title":"Clin Exp Metastasis"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2003.12.007","article-title":"In Situ Crosslinked Biodegradable Hydrogels Loaded With IL-2 Are Effective Tools for Local IL-2 Therapy","volume":"21","author":"Bos","year":"2004","journal-title":"Eur J Pharm Sci"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.01.008","article-title":"Injectable Hyaluronic Acid-Tyramine Hydrogels Incorporating Interferon-Alpha2a for Liver Cancer Therapy","volume":"166","author":"Xu","year":"2013","journal-title":"J Control Release"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.03.028","article-title":"Optimized Biodegradable Polymeric Reservoir-Mediated Local and Sustained Co-Delivery of Dendritic Cells and Oncolytic Adenovirus Co-Expressing IL-12 and GM-CSF for Cancer Immunotherapy","volume":"259","author":"Oh","year":"2017","journal-title":"J Control Release"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1126\/science.1232227","article-title":"Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet","volume":"339","author":"Coussens","year":"2013","journal-title":"Science"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2010.09.074","article-title":"Selective Inhibition of Cyclooxygenase-2 Suppresses Metastatic Disease Without Affecting Primary Tumor Growth in a Murine Model of Ewing Sarcoma","volume":"46","author":"Gendy","year":"2011","journal-title":"J\u00a0Pediatr Surg"},{"key":"B119","article-title":"Chemopreventive Activity of Celecoxib, A Specific Cyclooxygenase-2 Inhibitor, Against Colon Carcinogenesis","volume":"58","author":"Kawamori","year":"1998","journal-title":"Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1074374","article-title":"Hydrogel Dual Delivered Celecoxib and Anti-PD-1 Synergistically Improve Antitumor Immunity","volume":"5","author":"Li","year":"2016","journal-title":"Oncoimmunology"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2020.1869864","article-title":"Anti-Tumor Effect of Local Injectable Hydrogel-Loaded Endostatin Alone and in Combination With Radiotherapy for Lung Cancer","volume":"28","author":"Wang","year":"2021","journal-title":"Drug Deliv"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.a.37062","article-title":"Advances and Trends of Hydrogel Therapy Platform in Localized Tumor Treatment: A Review","volume":"109","author":"Tan","year":"2021","journal-title":"J BioMed Mater Res A"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120301","article-title":"Injectable Biodegradation-Visual Self-Healing Citrate Hydrogel With High Tissue Penetration for Microenvironment-Responsive Degradation and Local Tumor Therapy","volume":"261","author":"Wang","year":"2020","journal-title":"Biomaterials"},{"key":"B124","doi-asserted-by":"publisher","first-page":"101323","DOI":"10.1016\/j.nantod.2021.101323","article-title":"Peptide Hydrogels Loaded With Irradiated Tumor Cell Secretions Enhance Cancer Immunotherapy","volume":"41","author":"Wan","year":"2021","journal-title":"Nano Today"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.202100039","article-title":"Injectable Hydrogels as Local Depots at Tumor Sites for Antitumor Immunotherapy and Immune-Based Combination Therapy","volume":"21","author":"Ma","year":"2021","journal-title":"Macromol Biosci"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1039\/d1bm00971k","article-title":"Local Biomaterial-Assisted Antitumour Immunotherapy for Effusions in the Pleural and Peritoneal Cavities Caused by Malignancies","volume":"9","author":"Sun","year":"2021","journal-title":"Biomater Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.832942\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T02:28:17Z","timestamp":1642386497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.832942\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":126,"alternative-id":["10.3389\/fimmu.2021.832942"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.832942","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"article-number":"832942"}}